In the absence of effective antiviral chemotherapy and still in the context of emerging
vaccines for severe acute respiratory syndrome-CoV-2 infections, passive immunotherapy …

SARS-CoV-2 infection is a global public health threat. Vaccines are considered amongst the
most important tools to control the SARS-CoV-2 pandemic. As expected, deaths from SARS …

In recent years, fully human monoclonal antibodies (mAbs) are making up an increasing
share of the pharmaceutical market. However, to improve affinity and efficacy of antibodies …

Anomalies in protein–protein interactions may lead to a diseased state, as many cellular
functions are sustained by such interactions. These abnormal situations usually arise when …

SARS-CoV-2 exhibited limited widespread genetic variability over the first year of the COVID-
19 pandemic. However, approximately one year after its emergence, a slew of variants …

The COVID-19 pandemic erupted in 2019 and went on to have devastating impacts on
global health and economies. The causative agent of COVID-19 is a novel coronavirus …

Understanding how viruses and antibodies evolve in response to one another can help
inform future vaccines and therapies. This project investigated longitudinal samples from …

Background Nucleic acid detection represents limitations due to its false-negative rate and
technical complexity in the COVID-19 pandemic. Anti-severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus
disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting …

Neutralizing antibodies specifically block the infection of cells by viruses, such as the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their concentration in the sera of …